Foxhollow IPO Tabs $23 Mil. To Market Peripheral Plaque Excision System
This article was originally published in The Gray Sheet
Executive Summary
Foxhollow Technologies may need to submit a new investigational device exemption to resume a trial of its SilverHawk plaque excision system for coronary use following a device redesign, the firm says